{"id":"https://openalex.org/W4411287635","doi":"https://doi.org/10.1158/1557-3265.sabcs24-rf3-01","title":"Abstract RF3-01: TBCRC 056: A Phase II Study of Neoadjuvant Niraparib with Dostarlimab for Patients with BRCA- or PALB2-mutated Breast Cancer: Results From the ER+/HER2- Cohort","display_name":"Abstract RF3-01: TBCRC 056: A Phase II Study of Neoadjuvant Niraparib with Dostarlimab for Patients with BRCA- or PALB2-mutated Breast Cancer: Results From the ER+/HER2- Cohort","publication_year":2025,"publication_date":"2025-06-13","ids":{"openalex":"https://openalex.org/W4411287635","doi":"https://doi.org/10.1158/1557-3265.sabcs24-rf3-01"},"language":"en","primary_location":{"id":"doi:10.1158/1557-3265.sabcs24-rf3-01","doi":"https://doi.org/10.1158/1557-3265.sabcs24-rf3-01","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1557-3265.sabcs24-rf3-01","pdf_url":null,"source":{"id":"https://openalex.org/S183149254","display_name":"Clinical Cancer Research","issn_l":"1078-0432","issn":["1078-0432","1557-3265"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5111775802","display_name":"Erica L. Mayer","orcid":"https://orcid.org/0000-0001-5430-8957","observed_orcids":["https://orcid.org/0000-0001-5430-8957"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Erica Mayer","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090301769","display_name":"Noah Graham","orcid":"https://orcid.org/0009-0009-0622-683X","observed_orcids":["https://orcid.org/0009-0009-0622-683X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Noah Graham","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069569795","display_name":"Roberto Antonio Leon-Ferre","orcid":"https://orcid.org/0000-0003-0594-4441","observed_orcids":["https://orcid.org/0000-0003-0594-4441"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Roberto A. Leon-Ferre","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078936208","display_name":"Mariya Rozenblit","orcid":"https://orcid.org/0000-0003-0244-429X","observed_orcids":["https://orcid.org/0000-0003-0244-429X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mariya Rozenblit","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036750199","display_name":"Cesar Augusto Santa-Maria","orcid":"https://orcid.org/0000-0003-0979-8787","observed_orcids":["https://orcid.org/0000-0003-0979-8787"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Cesar Santa-Maria","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057580348","display_name":"Steven Jay Isakoff","orcid":"https://orcid.org/0000-0002-6677-1014","observed_orcids":["https://orcid.org/0000-0002-6677-1014"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Steven Isakoff","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024804370","display_name":"Jennifer M. Specht","orcid":"https://orcid.org/0000-0003-1484-2113","observed_orcids":["https://orcid.org/0000-0003-1484-2113"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jennifer Specht","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051532432","display_name":"Nadine Tung","orcid":"https://orcid.org/0000-0003-1422-3734","observed_orcids":["https://orcid.org/0000-0003-1422-3734"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Nadine Tung","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075889627","display_name":"Vandana Gupta Abramson","orcid":"https://orcid.org/0000-0002-6855-1322","observed_orcids":["https://orcid.org/0000-0002-6855-1322"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Vandana Abramson","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108939899","display_name":"Jennifer Desrosiers","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jennifer Desrosiers","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5116884161","display_name":"Beyza Koca","orcid":"https://orcid.org/0000-0002-8695-4424","observed_orcids":["https://orcid.org/0000-0002-8695-4424"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Beyza Koca","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069056507","display_name":"Sara M. Tolaney","orcid":"https://orcid.org/0000-0002-5940-8671","observed_orcids":["https://orcid.org/0000-0002-5940-8671"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sara M. Tolaney","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070245248","display_name":"Eric P. Winer","orcid":"https://orcid.org/0000-0002-8819-1723","observed_orcids":["https://orcid.org/0000-0002-8819-1723"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Eric P. Winer","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032785430","display_name":"Ian E. Krop","orcid":"https://orcid.org/0000-0002-6380-5944","observed_orcids":["https://orcid.org/0000-0002-6380-5944"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ian E. Krop","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026024346","display_name":"Antonio C. Wolff","orcid":"https://orcid.org/0000-0003-3734-1063","observed_orcids":["https://orcid.org/0000-0003-3734-1063"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Antonio C. Wolff","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045419282","display_name":"Geoffrey Ira Shapiro","orcid":"https://orcid.org/0000-0002-3331-4095","observed_orcids":["https://orcid.org/0000-0002-3331-4095"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Geoffrey I. Shapiro","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062515397","display_name":"Nabihah Tayob","orcid":"https://orcid.org/0000-0001-6088-167X","observed_orcids":["https://orcid.org/0000-0001-6088-167X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Nabihah Tayob","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5108281148","display_name":"Jennifer L. Guerriero","orcid":"https://orcid.org/0000-0002-2104-5457","observed_orcids":["https://orcid.org/0000-0002-2104-5457"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jennifer L. Guerriero","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":7,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"31","issue":"12_Supplement","first_page":"RF3","last_page":"01"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.9940999746322632,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.9940999746322632,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10769","display_name":"BRCA gene mutations in cancer","score":0.005499999970197678,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/niraparib","display_name":"niraparib","score":0.8669999837875366},{"id":"https://openalex.org/keywords/dostarlimab","display_name":"dostarlimab","score":1.0},{"id":"https://openalex.org/keywords/neoadjuvant-therapy","display_name":"neoadjuvant therapy","score":0.9629999995231628},{"id":"https://openalex.org/keywords/hormone-receptor-positive-breast-cancer","display_name":"hormone receptor-positive breast cancer","score":0.8220000267028809},{"id":"https://openalex.org/keywords/her2-negative-breast-cancer","display_name":"HER2-negative breast cancer","score":0.9649999737739563},{"id":"https://openalex.org/keywords/parp-inhibitors","display_name":"PARP inhibitors","score":0.8220000267028809},{"id":"https://openalex.org/keywords/anti-pd-1-therapy","display_name":"anti-PD-1 therapy","score":0.7879999876022339},{"id":"https://openalex.org/keywords/pathological-complete-response","display_name":"pathological complete response","score":0.8679999709129333},{"id":"https://openalex.org/keywords/stromal-tumor-infiltrating-lymphocytes","display_name":"stromal tumor-infiltrating lymphocytes","score":0.9240000247955322},{"id":"https://openalex.org/keywords/cgas-sting-pathway","display_name":"cGAS-STING pathway","score":0.9169999957084656}],"concepts":[{"id":"https://openalex.org/C2778144015","wikidata":"https://www.wikidata.org/wiki/Q18046302","display_name":"PALB2","level":5,"score":0.8945457935333252},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7374714016914368},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.6365847587585449},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6262418031692505},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.5391867756843567},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.47883298993110657},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3646140694618225},{"id":"https://openalex.org/C501734568","wikidata":"https://www.wikidata.org/wiki/Q42918","display_name":"Mutation","level":3,"score":0.15151473879814148},{"id":"https://openalex.org/C13514818","wikidata":"https://www.wikidata.org/wiki/Q5552256","display_name":"Germline mutation","level":4,"score":0.1469726860523224},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.13142651319503784},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.06371933221817017},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1557-3265.sabcs24-rf3-01","doi":"https://doi.org/10.1158/1557-3265.sabcs24-rf3-01","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1557-3265.sabcs24-rf3-01","pdf_url":null,"source":{"id":"https://openalex.org/S183149254","display_name":"Clinical Cancer Research","issn_l":"1078-0432","issn":["1078-0432","1557-3265"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4391375266","https://openalex.org/W3120903239","https://openalex.org/W2980592321","https://openalex.org/W3132804527","https://openalex.org/W2136773734","https://openalex.org/W1972696984","https://openalex.org/W3162370541","https://openalex.org/W3083417375","https://openalex.org/W4286218440","https://openalex.org/W2892677547"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"PARP":[2],"inhibitors":[3,633],"(PARPi)":[4],"have":[5,376],"an":[6,74],"approved":[7],"role":[8],"in":[9,20,30,91,132,153,227,238,248,250,273,598,634,652],"treating":[10],"patients":[11],"(pts)":[12],"with":[13,26,32,61,85,101,180,257,262,312,382,398,430,459,517,546,567,586,710,714],"germline":[14],"BRCA1/2":[15],"mutated":[16],"(gBRCAm)":[17],"breast":[18,99,107,314,589,640],"cancer":[19,108,315],"the":[21,44,81,86,92,288,475,619,628,635,722,729],"advanced":[22],"and":[23,52,112,114,140,167,184,241,246,277,287,292,318,323,349,361,471,506,522,595,604],"early":[24,409,441],"settings,":[25],"activity":[27,630],"also":[28],"seen":[29],"pts":[31,131,152,193,311,367,375,406,423,438,477,516,585],"gPALB2m.":[33],"Preclinical":[34],"data":[35,617],"suggest":[36],"PARPi":[37,62,82,594],"exposure":[38],"leads":[39],"to":[40,56,218,235,259,304],"intratumoral":[41],"activation":[42],"of":[43,95,144,159,244,373,396,401,415,428,433,447,551,593,602,609,611,622,631,638,644,649,707,728],"proinflammatory":[45],"cGAS/STING":[46],"pathway,":[47],"recruiting":[48],"CD8+":[49],"T":[50],"cells,":[51],"sensitizing":[53],"gBRCAm":[54,96,137,587],"cancers":[55],"immune-targeted":[57],"therapy.":[58],"Preoperative":[59],"treatment":[60,94],"monotherapy":[63],"has":[64],"demonstrated":[65],"notable":[66],"pathologic":[67],"complete":[68],"response":[69,480],"(pCR)":[70],"rates.":[71],"TBCRC":[72,701],"056,":[73],"open-label":[75],"randomized":[76],"phase":[77],"II":[78,705],"study,":[79],"evaluates":[80],"niraparib":[83],"(N)":[84],"anti-PD-1":[87],"antibody":[88],"dostarlimab":[89],"(D)":[90],"neoadjuvant":[93],"or":[97,138,197,716],"gPALB2mHER2-negative":[98],"cancer,":[100,590,641],"cohorts":[102],"for":[103,385,479,712],"both":[104],"triple":[105],"negative":[106],"(TNBC,":[109],"Arms":[110,239],"A":[111,240,703],"B)":[113],"hormone":[115],"receptor":[116],"positive":[117],"(HR+)":[118],"disease":[119,208,499],"(Arm":[120],"C).":[121],"Results":[122,720],"from":[123,233,618],"Arm":[124,133,154,251,305],"C":[125,134,155,252,306],"are":[126,217,253,625],"being":[127],"presented.":[128],"Methods:":[129],"Eligible":[130],"had":[135,368,485,497],"a":[136,141,263,283,297,547,560,599,605],"gPALB2m":[139],"tumor":[142,188,229],"size":[143],">1.0":[145],"cm,":[146],"ER":[147],"and/or":[148],"PR+":[149],"(>10%).":[150],"All":[151,365],"received":[156,198,403,435,509],"18":[157,191,310,366,374,591],"weeks":[158,174,237,279,592],"combination":[160],"N":[161,429,440],"200":[162],"mg":[163,170],"orally":[164],"once":[165],"daily":[166],"D":[168,397,408],"500":[169],"IV":[171],"every":[172],"3":[173,178,186,236,278,484,523,539,614],"(1":[175,410,442],"cycle":[176],"=":[177,581],"weeks),":[179],"mandatory":[181],"baseline":[182],"(BL)":[183],"week":[185,538],"core":[187],"biopsies.":[189],"After":[190],"weeks,":[192,524],"either":[194],"underwent":[195],"surgery":[196,222,488],"additional":[199,510,642],"preoperative":[200,636],"systemic":[201],"therapy":[202,379],"(per":[203],"physician\u2019s":[204],"choice)":[205],"if":[206],"residual":[207,498],"was":[209,280,294,307,336,354,529,540,565],"present":[210],"on":[211],"imaging.":[212],"The":[213,452],"primary":[214],"study":[215,255,624],"objectives":[216],"evaluate":[219],"pCR":[220,245,258,293,486,568,600],"at":[221,481,487,520,527,537,563,613],"as":[223,225],"well":[224],"change":[226,247],"stromal":[228],"infiltrating":[230],"lymphocytes":[231],"(sTILs)":[232],"BL":[234,276,521,528,564],"B.":[242],"Evaluation":[243],"sTILs":[249,274,291,519,526,536,558,610],"secondary":[254],"objectives,":[256],"be":[260],"reported":[261,629],"two-sided":[264],"exact":[265],"90%":[266],"confidence":[267],"interval":[268],"without":[269],"hypothesis":[270],"testing.":[271],"Change":[272],"between":[275,290,320],"evaluated":[281],"using":[282,296],"Wilcoxon":[284,298,553,577],"signed-rank":[285],"test,":[286],"association":[289],"assessed":[295],"rank":[299,555,578],"sum":[300,579],"test.":[301],"Results:":[302],"Accrual":[303],"completed":[308,377,393,425],"after":[309],"HR+/HER2-":[313,588],"were":[316,342,461],"enrolled":[317],"treated":[319],"April":[321],"2021":[322],"May":[324],"2024":[325,736],"(5":[326],"gBRCA1m":[327],"(27.8%),":[328],"13":[329],"gBRCA2m":[330],"(72.2%),":[331],"0":[332],"gPALB2m).":[333],"Median":[334],"age":[335],"41.8":[337],"years":[338],"(range":[339,531,542],"28.8-61.9),":[340],"14":[341],"self-reported":[343],"White":[344],"(77.8%),":[345],"4":[346,417,502,504],"(22.2%)":[347],"Black,":[348],"none":[350],"Hispanic.":[351],"Stage":[352],"distribution":[353],"38.9%":[355],"stage":[356,359,363],"I,":[357],"44.5%":[358],"II,":[360],"16.7%":[362],"III.":[364],"ER+":[369],">10%":[370],"disease.":[371],"Sixteen":[372],"protocol":[378],"through":[380],"surgery,":[381],"results":[383],"pending":[384],"2":[386,507],"pts.":[387],"Among":[388,514],"evaluable":[389,478,518],"pts,":[390],"10":[391],"(62.5%)":[392],"6":[394,426],"cycles":[395,402,427,434],"mean":[399,431,525,535,548,606],"number":[400,432],"4.7.":[404],"Six":[405],"discontinued":[407,439],"progressive":[411,443],"disease,":[412,444],"1":[413,445,449],"withdrawal":[414,446],"consent,":[416,448],"unacceptable":[418,450],"adverse":[419],"events":[420],"(AE)).":[421],"Thirteen":[422],"(81.2%)":[424],"5.4.":[436],"Three":[437],"AE).":[451],"most":[453],"common":[454],"AE":[455],"(>":[456],"grade":[457],"2)":[458],"D+N":[460],"rash":[462],"(25.0%),":[463],"elevated":[464],"liver":[465],"function":[466],"tests":[467],"(18.8%),":[468],"diarrhea":[469],"(12.5%),":[470],"hypertension":[472],"(12.5%).":[473],"Of":[474],"16":[476],"this":[482,623,653],"time,":[483],"(18.8%,":[489],"(90%":[490],"CI":[491,573],"5.3%":[492],"-":[493,544],"41.7%)),":[494],"11":[495],"(68.8%)":[496],"(3":[500],"RCB-I,":[501],"RCB-II,":[503],"RCB-III),":[505],"(12.5%)":[508],"chemotherapy":[511],"before":[512],"surgery.":[513],"12":[515],"11.9%":[530,612],"1.0%":[532],"\u2013":[533,575],"35.0%),":[534],"23.8%":[541],"5.0%":[543],"90.0%),":[545],"absolute":[549,607],"increase":[550,608],"11.9%;":[552],"signed":[554],"p=0.09).":[556],"Higher":[557],"(as":[559],"continuous":[561],"variable)":[562],"associated":[566],"(odds":[569],"ratio":[570],"1.09,":[571],"95%":[572],"1.00":[574],"1.19,":[576],"p":[580],"0.03).":[582],"Conclusions:":[583],"In":[584],"anti-PD1":[596],"resulted":[597],"rate":[601],"18.8%,":[603],"weeks.":[615],"Further":[616],"TNBC":[620],"cohort":[621],"awaited.":[626],"Given":[627],"PD-1":[632],"management":[637],"HR+":[639],"exploration":[643],"targeted":[645],"non-chemotherapy":[646],"approaches":[647],"is":[648],"great":[650],"interest":[651],"pt":[654],"population.":[655],"Citation":[656],"Format:":[657],"Erica":[658],"Mayer,":[659],"Noah":[660],"Graham,":[661],"Roberto":[662],"A.":[663],"Leon-Ferre,":[664],"Mariya":[665],"Rozenblit,":[666],"Cesar":[667],"Santa-Maria,":[668],"Steven":[669],"Isakoff,":[670],"Jennifer":[671,677,698],"Specht;":[672],"Nadine":[673],"Tung,":[674],"Vandana":[675],"Abramson,":[676],"Desrosiers,":[678],"Beyza":[679],"Koca,":[680],"Sara":[681],"M.":[682],"Tolaney,":[683],"Eric":[684],"P.":[685],"Winer,":[686],"Ian":[687],"E.":[688],"Krop,":[689],"Antonio":[690,731],"C.":[691],"Wolff,":[692],"Geoffrey":[693],"I.":[694],"Shapiro,":[695],"Nabihah":[696],"Tayob,":[697],"L.":[699],"Guerriero.":[700],"056:":[702],"Phase":[704],"Study":[706],"Neoadjuvant":[708],"Niraparib":[709],"Dostarlimab":[711],"Patients":[713],"BRCA-":[715],"PALB2-mutated":[717],"Breast":[718,732],"Cancer:":[719],"From":[721],"ER+/HER2-":[723],"Cohort":[724],"[abstract].":[725],"In:":[726],"Proceedings":[727],"San":[730,739],"Cancer":[733,746],"Symposium":[734],"2024;":[735],"Dec":[737],"10-13;":[738],"Antonio,":[740],"TX.":[741],"Philadelphia":[742],"(PA):":[743],"AACR;":[744],"Clin":[745],"Res":[747],"2025;31(12":[748],"Suppl):Abstract":[749],"nr":[750],"RF3-01.":[751]},"counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":3}],"updated_date":"2026-10-17T09:40:24.721904","created_date":"2025-10-10T00:00:00"}